Your browser doesn't support javascript.
loading
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.
Rossi, Cédric; André, Marc; Dupuis, Jehan; Morschhauser, Franck; Joly, Bertrand; Lazarovici, Julien; Ghesquières, Hervé; Stamatoullas, Aspasia; Nicolas-Virelizier, Emmanuelle; Feugier, Pierre; Gac, Anne-Claire; Moatti, Hannah; Fornecker, Luc-Matthieu; Deau, Bénédicte; Joubert, Clémentine; Fortpied, Catherine; Raemaekers, John; Federico, Massimo; Kanoun, Salim; Meignan, Michel; Traverse-Glehen, Alexandra; Cottereau, Anne-Ségolène; Casasnova, René-Olivier.
Affiliation
  • Rossi C; Department of Hematology, Dijon-Bourgogne University Hospital, Dijon; INSERM unit 1231, University of Burgundy Franche-Comté, France. cedric.rossi66@gmail.com.
  • André M; Department of Hematology, CHU UCL Namur, Université Catholique de Louvain, Yvoir, Belgium.
  • Dupuis J; Lymphoid Malignancies Unit, Henri Mondor University Hospital (AP-HP), Créteil, France.
  • Morschhauser F; Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), Department of Haematology, CHU Lille, Université de Lille, Lille.
  • Joly B; Department of Hematology, Hospital Sud Francilien, Corbeille-Essonnes, France.
  • Lazarovici J; Department of Hematology, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
  • Ghesquières H; Department of Hematology, Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre-Bénite, France.
  • Stamatoullas A; Department of Hematology, Centre Henri Becquerel, Rouen, France.
  • Nicolas-Virelizier E; Department of Hematology, Centre Léon Bérard, Lyon, France.
  • Feugier P; Hospital of Nancy, Vandoeuvre les Nancy, France.
  • Gac AC; Department of Haematology, Institut d'hématologie de Basse Normandie, Caen, France.
  • Moatti H; Department of Hematology, CHU Paris-GH St-Louis Lariboisière F-Widal - Hôpital Saint-Louis, Paris, France.
  • Fornecker LM; Department of Haematology, University Hospital of Strasbourg, Strasbourg, France.
  • Deau B; Department of Hematology, CHU Cochin, Paris, France.
  • Joubert C; Lymphoma Academic Research Organisation, CHU Lyon-Sud, Lyon, France.
  • Fortpied C; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Raemaekers J; Department of Haematology, Radboud University Medical Center, Nijmegen, Netherlands.
  • Federico M; CHIMOMO department, University of Modena and Reggio Emilia, Policlinico, Modena, Italy.
  • Kanoun S; Nuclear Medecine Unit, Institut universitaire du cancer Toulouse-Oncopole, Toulouse, France.
  • Meignan M; LYSA Imaging, University Hospital H Mondor, Creteil, France.
  • Traverse-Glehen A; Department of Pathology, Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite, France.
  • Cottereau AS; Nuclear Medecine Department, Hôpital Cochin, AP-HP, Université de Paris, France.
  • Casasnova RO; Department of Hematology, Dijon-Bourgogne University Hospital, Dijon; INSERM unit 1231, University of Burgundy Franche-Comté, France.
Haematologica ; 107(12): 2897-2904, 2022 12 01.
Article in En | MEDLINE | ID: mdl-35638548
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Haematologica Year: 2022 Type: Article Affiliation country: France
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Haematologica Year: 2022 Type: Article Affiliation country: France